Logo image of BLND

BLEND LABS INC-A (BLND) Stock Fundamental Analysis

NYSE:BLND - New York Stock Exchange, Inc. - US09352U1088 - Common Stock - Currency: USD

3.49  +0.02 (+0.58%)

After market: 3.49 0 (0%)

Fundamental Rating

3

Overall BLND gets a fundamental rating of 3 out of 10. We evaluated BLND against 282 industry peers in the Software industry. The financial health of BLND is average, but there are quite some concerns on its profitability. While showing a medium growth rate, BLND is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

BLND had negative earnings in the past year.
In the past year BLND had a positive cash flow from operations.
BLND had negative earnings in each of the past 5 years.
In the past 5 years BLND always reported negative operating cash flow.
BLND Yearly Net Income VS EBIT VS OCF VS FCFBLND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

BLND has a worse Return On Assets (-28.17%) than 73.05% of its industry peers.
Looking at the Return On Equity, with a value of -41.12%, BLND is doing worse than 64.89% of the companies in the same industry.
Industry RankSector Rank
ROA -28.17%
ROE -41.12%
ROIC N/A
ROA(3y)-100.5%
ROA(5y)-70.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLND Yearly ROA, ROE, ROICBLND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

With a Gross Margin value of 59.39%, BLND is not doing good in the industry: 61.70% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of BLND has declined.
The Profit Margin and Operating Margin are not available for BLND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
BLND Yearly Profit, Operating, Gross MarginsBLND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

6

2. Health

2.1 Basic Checks

BLND does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLND has been increased compared to 1 year ago.
BLND has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BLND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLND Yearly Shares OutstandingBLND Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
BLND Yearly Total Debt VS Total AssetsBLND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

BLND has an Altman-Z score of -0.41. This is a bad value and indicates that BLND is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.41, BLND is doing worse than 73.40% of the companies in the same industry.
BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.41
ROIC/WACCN/A
WACC11.13%
BLND Yearly LT Debt VS Equity VS FCFBLND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.41 indicates that BLND has no problem at all paying its short term obligations.
The Current ratio of BLND (2.41) is better than 69.50% of its industry peers.
BLND has a Quick Ratio of 2.41. This indicates that BLND is financially healthy and has no problem in meeting its short term obligations.
BLND's Quick ratio of 2.41 is fine compared to the rest of the industry. BLND outperforms 70.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.41
BLND Yearly Current Assets VS Current LiabilitesBLND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

5

3. Growth

3.1 Past

BLND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.97%, which is quite impressive.
Looking at the last year, BLND shows a decrease in Revenue. The Revenue has decreased by -0.40% in the last year.
The Revenue has been growing by 26.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)96.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)-0.4%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%-23.4%

3.2 Future

The Earnings Per Share is expected to grow by 67.05% on average over the next years. This is a very strong growth
Based on estimates for the next years, BLND will show a quite strong growth in Revenue. The Revenue will grow by 9.48% on average per year.
EPS Next Y163.75%
EPS Next 2Y86.18%
EPS Next 3Y67.05%
EPS Next 5YN/A
Revenue Next Year-18.51%
Revenue Next 2Y2.36%
Revenue Next 3Y9.48%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BLND Yearly Revenue VS EstimatesBLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
BLND Yearly EPS VS EstimatesBLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLND. In the last year negative earnings were reported.
BLND is valuated quite expensively with a Price/Forward Earnings ratio of 29.75.
Based on the Price/Forward Earnings ratio, BLND is valued a bit cheaper than 65.25% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BLND to the average of the S&P500 Index (36.71), we can say BLND is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 29.75
BLND Price Earnings VS Forward Price EarningsBLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLND Per share dataBLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

BLND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BLND's earnings are expected to grow with 67.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.18%
EPS Next 3Y67.05%

0

5. Dividend

5.1 Amount

BLND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BLEND LABS INC-A

NYSE:BLND (7/22/2025, 8:04:01 PM)

After market: 3.49 0 (0%)

3.49

+0.02 (+0.58%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners64.4%
Inst Owner Change0.46%
Ins Owners3.94%
Ins Owner Change4.33%
Market Cap902.23M
Analysts80
Price Target5.11 (46.42%)
Short Float %3.27%
Short Ratio3.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)61.27%
Min EPS beat(2)-100%
Max EPS beat(2)222.55%
EPS beat(4)3
Avg EPS beat(4)69.5%
Min EPS beat(4)-100%
Max EPS beat(4)222.55%
EPS beat(8)6
Avg EPS beat(8)41.39%
EPS beat(12)8
Avg EPS beat(12)26.45%
EPS beat(16)10
Avg EPS beat(16)-21.63%
Revenue beat(2)0
Avg Revenue beat(2)-16.29%
Min Revenue beat(2)-30.67%
Max Revenue beat(2)-1.91%
Revenue beat(4)2
Avg Revenue beat(4)-6.29%
Min Revenue beat(4)-30.67%
Max Revenue beat(4)5.71%
Revenue beat(8)3
Avg Revenue beat(8)-3.32%
Revenue beat(12)6
Avg Revenue beat(12)-0.38%
Revenue beat(16)8
Avg Revenue beat(16)-3.92%
PT rev (1m)0%
PT rev (3m)-2.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)38.92%
EPS NY rev (1m)25%
EPS NY rev (3m)7.14%
Revenue NQ rev (1m)-6.37%
Revenue NQ rev (3m)-28.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-27.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 29.75
P/S 5.86
P/FCF N/A
P/OCF 80.46
P/B 7
P/tB 7
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)0.12
Fwd EY3.36%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY1.24%
SpS0.6
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.17%
ROE -41.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.39%
FCFM N/A
ROA(3y)-100.5%
ROA(5y)-70.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.15%
GM growth 5Y-1.85%
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 584.76%
Cap/Sales 8.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.41
Altman-Z -0.41
F-Score6
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)157.7%
Cap/Depr(5y)104.5%
Cap/Sales(3y)2.44%
Cap/Sales(5y)1.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y163.75%
EPS Next 2Y86.18%
EPS Next 3Y67.05%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.4%
Revenue growth 3Y-11.6%
Revenue growth 5Y26.16%
Sales Q2Q%-23.4%
Revenue Next Year-18.51%
Revenue Next 2Y2.36%
Revenue Next 3Y9.48%
Revenue Next 5YN/A
EBIT growth 1Y71.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year205.84%
EBIT Next 3Y86.13%
EBIT Next 5YN/A
FCF growth 1Y99.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.86%
OCF growth 3YN/A
OCF growth 5YN/A